RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY;THE BROAD INSTITUTE, INC.
发明人:
Hu Longqin,Magesh Sadagopan,Chen Lin,Lewis Timothy,Munoz Ben,Wang Lili
申请号：
US201715718987
公开号：
US10106502(B2)
申请日:
2017.09.28
申请国别(地区):
美国
年份:
2018
代理人:
Fox Rothschild LLP
摘要：
A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.
